Conclusions
RECURRENCE
This analysis of the Japanese subgroup of patients enrolled in CheckMate 274 was consistent with the overall results of DFS and NUTRFS. We also observed no impairment in QOL, as measured using the EORTC QLQ-C30. The safety profile of nivolumab in Japanese patients was consistent with that in the overall study population, and no new safety concerns were reported. In conclusion, the present results, combined with those of the overall study population, suggest that nivolumab could be useful as adjuvant therapy for Japanese patients with MIUC at high risk of recurrence after radical surgery.